Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study
Open Access
- 17 October 2017
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 36 (2) , 215-223
Abstract
Objective The aim of this study was to investigate the impact of adverse events (AEs) on health utility and health-related quality of life (HRQOL) in patients with metastatic breast cancer undergoing first-line chemotherapy. Methods We analyzed the data from the SELECT BC study, a multicenter, open-label, randomized, phase III study conducted in Japan, which compared first-line S-1 with taxane therapies. Heath utility and HRQOL were assessed using the EQ-5D-3L and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) at baseline and 3, 6, and 12 months after treatment initiation. Health utility was calculated based on societal preferences, and AEs were reported at each cycle of the study treatment. Linear marginal mean models were used to quantify the impact of the last AEs (with 10 or more incidences) observed before HRQOL assessment on health utility and HRQOL. Results Analysis included 380 patients and 12 (of 15) AEs. Grade 1 nausea and oral mucositis, grade 1 and 2 edema, and grade 2 fatigue, motor and sensory neuropathy, and myalgia were significantly associated with disutility, measured using the EQ-5D-3L. Grade 1 oral mucositis, grade 1 and 2 fatigue, and grade 2 sensory neuropathy were significantly associated with impaired global health status in the EORTC QLQ-C30. AEs associated with decrements in the five functioning scales included fatigue, oral mucositis, nausea, edema, motor and sensory neuropathy, and myalgia. Conclusions We reported disutilities caused by AEs in patients with metastatic breast cancer under chemotherapy. These findings can be applied to future model-based cost-effectiveness analyses. Trial Registration Number C000000416.Keywords
Funding Information
- Comprehensive Support Project for Oncology Research of Public Health Research Foundation
- Taiho Pharmaceutical
This publication has 34 references indexed in Scilit:
- A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancerBreast Cancer Research and Treatment, 2015
- Global cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2015
- Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2014
- Economic Evaluations of Medical Care Interventions for Cancer Patients: How, Why, and What Does it Mean?CA: A Cancer Journal for Clinicians, 2008
- Methodological issues in the economic analysis of cancer treatmentsEuropean Journal of Cancer, 2006
- Health state utilities for metastatic breast cancerBritish Journal of Cancer, 2006
- Extending Survival with Chemotherapy in Metastatic Breast CancerThe Oncologist, 2005
- Cost Effectiveness of Treatment Options in Advanced Breast Cancer in the UKPharmacoEconomics, 2001
- Cost-Utility Analysis of Chemotherapy Using Paclitaxel, Docetaxel, or Vinorelbine for Patients With Anthracycline-Resistant Breast CancerJournal of Clinical Oncology, 1999
- Effect of chemotherapy on survival in metastatic breast cancerBreast Cancer Research and Treatment, 1981